7-chloro-thieno[3,2-b]pyridine-2-carboxylic acid dimethylamide | 380235-49-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 7-chloro-thieno[3,2-b]pyridine-2-carboxylic acid dimethylamide
• 英文别名: 7-chloro-N,N-dimethylthieno[3,2-b]pyridine-2-carboxamide
• CAS: 380235-49-4
• 化学式: C₁₀H₉ClN₂OS
• 分子量: 240.713
• InChiKey: ZFVBOLLDXJZHQP-UHFFFAOYSA-N

物化性质

• 沸点：
  396.4±37.0 °C(Predicted)
• 密度：
  1.387±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  61.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-氨基-2-甲基吲哚 、 7-chloro-thieno[3,2-b]pyridine-2-carboxylic acid dimethylamide 生成 7-(2-Methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridine-2-carboxylic Acid Dimethylamide
  参考文献：
  名称：

  Thiophene derivatives useful as anticancer agents

  摘要：

  本发明涉及公式1的化合物或其药学上可接受的盐和水合物，其中X，Y，R1，R2和R11如本文所定义。本发明还涉及含有公式1化合物的药物组合物以及通过给予公式1化合物治疗哺乳动物的增生性疾病的方法。

  公开号：

  US06964961B2
• 作为产物：
  描述：

  7-chlorothieno[3,2-b] pyridine-2-carbonyl chloride 、 二甲胺 以 二氯甲烷 为溶剂， 生成 7-chloro-thieno[3,2-b]pyridine-2-carboxylic acid dimethylamide
  参考文献：
  名称：

  Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases

  摘要：

  A series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases is described. The compounds demonstrated potency with IC50 values in the low nanomolar range in vitro while the lead compound also showed in vivo activity against various human tumor xenograft models in mice. Further exploration of this class of compounds is underway. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.009

文献信息

• Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US20040009965A1

  公开（公告）日：2004-01-15

  The invention relates to compounds represented by the formula I 1 and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R 11 and R 14 , R 15 , R 16 , and R 17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

  这项发明涉及由公式I1表示的化合物，以及这些化合物的前药或代谢物，或这些化合物的药用可接受的盐或溶剂，所述前药和所述代谢物，其中Z、Y、R11和R14、R15、R16和R17如本文所定义。该发明还涉及含有公式I化合物的药物组合物，以及通过给哺乳动物施用公式I化合物来治疗过度增殖性疾病的方法。
• [EN] INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING<br/>[FR] INHIBITEURS DE SIGNALISATION DE RECEPTEUR DU FACTEUR DE CROISSANCE ENDOTHELIALE (VEGF) ET DE RECEPTEUR DE FACTEUR DE CROISSANCE DES HEPATOCYTES (HGF)
  申请人：METHYLGENE INC

  公开号：WO2006010264A1

  公开（公告）日：2006-02-02

  The invention relates to the inhibition of vascular endothelial growth factor (VEGF) receptor signaling and hepatocyte growth factor (HGF) receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

  该发明涉及抑制血管内皮生长因子（VEGF）受体信号和肝细胞生长因子（HGF）受体信号的方法。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和症状的组合物和方法。
• [EN] THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS<br/>[FR] THIENOPYRIDINE-PHENYLACETAMIDES ET LEURS DERIVES UTILES COMME NOUVEAUX AGENTS ANTI-ANGIOGENIQUES
  申请人：PFIZER

  公开号：WO2005021554A1

  公开（公告）日：2005-03-10

  The invention relates to compounds represented by Formula (I):, and to prodrugs thereof, pharmaceutically salts or solvates of said compounds or said prodrugs, wherein each of X1-X5 and R1-R5 are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).

  这项发明涉及由化学式（I）表示的化合物，以及这些化合物的前药、药用盐或溶剂化合物或前药，其中X1-X5和R1-R5各自在此处定义。该发明还涉及含有化合物的药物组合物的制备方法，并通过给予化合物治疗哺乳动物的高增殖性疾病的方法。
• INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING
  申请人：Saavedra Mario Oscar

  公开号：US20060287343A1

  公开（公告）日：2006-12-21

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

  本发明涉及抑制VEGF受体信号和HGF受体信号的方法。本发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。本发明还提供了用于治疗细胞增殖性疾病和病状的组合物和方法。
• Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents
  申请人：Lou Jihong

  公开号：US20050090509A1

  公开（公告）日：2005-04-28

  The invention relates to compounds represented by Formula (I): and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein each of X 1 -X 5 and R 1 -R 5 are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).

  本发明涉及由式（I）表示的化合物，以及其前药、所述化合物或所述前药的药学上可接受的盐或溶剂，其中X1-X5和R1-R5中的每个都在此定义。本发明还涉及含有式（I）的化合物的制剂，以及通过给予式（I）化合物治疗哺乳动物的增殖性疾病的方法。